



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BS

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/007,255	10/25/2001	Sean P. Colgan	B0801/7233	5204
7590	02/14/2005		EXAMINER	
Elizabeth R. Plumer Wolf, Greenfield & Sacks, P.C. Federal Reserve Plaza 600 Atlantic Avenue Boston, MA 02210			YU, MISOOK	
			ART UNIT	PAPER NUMBER
			1642	
			DATE MAILED: 02/14/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/007,255	COLGAN, SEAN P.	
	Examiner	Art Unit	
	MISOOK YU, Ph.D.	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 01 November 2004.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 14 and 15 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 14 and 15 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 12/30/02, 2/3/03, 3/20/03

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.

5) Notice of Informal Patent Application (PTO-152)

6) Other: See Continuation Sheet.

Continuation of Attachment(s) 6). Other: Exhibit A (seq. alignment, 3 pages).

DETAILED ACTION

Applicant's election of group IV with species of SEQ ID NO:9 in the reply filed on 1101/2004 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 14, and 15 are pending and examined on merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 15 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is "undue" include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

This rejection is made because claim 15 recites “pharmaceutical” comprising SEQ ID NO:9 nucleic acid. The specification at pages 40-42 discloses mdr1 antisense. However, the specification does not teach how to use nucleic acid comprising instant SEQ ID NO:9 as pharmaceutical. The specification does not provide a sufficient amount of guidance, direction, or exemplification to enable the skilled artisan to make or use a pharmaceutical comprising the instant SEQ ID NO:9

The art of gene therapy, i.e., the *in vivo* delivery genetic information to targeted cells within a body using naked DNA or viral vectors or by reintroducing *ex vivo* modified host cells into the body, is still in its infancy. Moreover, the art is highly unpredictable and its successful application has been hindered by numerous limitations, which the specification does not remedy and would preclude the skilled artisan from having a reasonable expectation of successfully making and using the claimed invention without need of performing an undue amount of experimentation. For example, the teachings of the specification have not overcome the problems with *in vivo* delivery and expression. Verma et al. (*Nature* 1997, **389**: 239-242) teach that the ongoing problem is the inability to deliver genes efficiently and to obtain sustained expression. Izquierdo (2004, *Cancer Therapy*, 1-11) also teaches that “the ability to deliver efficiently sufficient amounts of siRNA” to a particular site is the problem that faces the iRNA art (note the last paragraph at page 8). The art recognizes that gene therapy is not a trivial matter. The specification does not teach any method of overcoming technical difficulties the art has been facing with the gene therapy. Thus, based on the state of art, one of skill in the art would have a reason to doubt the efficacy of the claimed pharmaceutical.

Considering the unpredictable state of art, limited guidance, no examples in the specification how to use the instantly claimed invention as a pharmaceutical, it is concluded that undue experimentation is required to practice the invention.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 14, and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by either US Pat. 5,968,735 (Oct. 19, 1999).

Claims 14, and 15 are interpreted as drawn to an isolated comprising SEQ ID NO:9 (the elected species).

US Pat. 5,968,735 teaches an isolated nucleic acid comprising instant SEQ ID NO:9, i.e. SEQ ID NO:1-4. Note the attached sequence alignment (Exhibit A) showing that instant SEQ ID NO:9 matches 100% to 24 nucleotides within SEQ ID NOs 1-4 of US Pat. 5,968,735. Since instant claims are construed using the open transitional phrase “comprising” as to the scope of the unrecited part of the claimed nucleic acid, the instant claims read on SEQ ID NOs 1-4 of US Pat. 5,968,735. Note that the phrase “the group consisting of” is a Markush language indicating an alternate choice.

As to the preamble “pharmaceutical” in claim 15, the preamble is not given patentable weight for purposes of comparing the claim with the prior art. The claim reads on the nucleic acid per se.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MISOOK YU, Ph.D.
Examiner
Art Unit 1642



MISOOK YU
PATENT EXAMINER

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using SW model
Run on: February 9, 2005, 13:42:01 ; Search time 75.4483 seconds
520.498 Million cell updates/sec

Title: US-10-007-255-9
perfect score: 24
Sequence: 1 cttatgttagacacgctttcaag 24

Scoring table: IDENTITY_NUC
Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 2405568

Minimum DB seq length: 0
Maximum DB seq length: 0
Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : Issued Patents No.:#
1: /cg912_6/podata/lina/5A_COMB.seq: *
2: /cg912_6/podata/lina/5B_COMB.seq: *
3: /cg912_6/podata/lina/6A_COMB.seq: *
4: /cg912_6/podata/lina/6B_COMB.seq: *
5: /cg912_6/podata/lina/CCUS_COMB.seq: *
6: /cg912_6/podata/lina/backfile1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
C 1	24	100.0	568	2 US-08-439-814-4 Sequence 4, Appli
C 2	24	100.0	1318	2 US-08-439-814-3 Sequence 3, Appli
C 3	24	100.0	1688	2 US-08-439-814-2 Sequence 2, Appli
C 4	24	100.0	2090	2 US-08-439-814-1 Sequence 1, Appli
C 5	17.2	71.7	601	4 US-09-949-016-170890 Sequence 70890, A
C 6	17.2	71.7	13204	4 US-09-949-016-272749 Sequence 49, Appli
C 7	17.2	71.7	13536	4 US-09-949-016-14186 Sequence 14186, A
C 8	17.2	71.7	15294	4 US-09-949-016-18840 Sequence 13899, A
C 9	17.2	71.7	276687	4 US-09-949-016-18840 Sequence 17500, A
C 10	17	70.8	92	4 US-09-621-976-17500 Sequence 17501, A
C 11	17	70.8	103	4 US-09-621-976-17501 Sequence 17502, A
C 12	17	70.8	126	4 US-09-621-976-17503 Sequence 17503, A
C 13	17	70.8	137	4 US-09-621-976-17502 Sequence 17504, A
C 14	17	70.8	150	4 US-09-621-976-17502 Sequence 17505, A
C 15	17	70.8	169	4 US-09-621-976-17502 Sequence 17506, A
C 16	17	70.8	179	4 US-09-621-976-17502 Sequence 17507, A
C 17	16.8	70.0	26313	4 US-09-949-016-16117 Sequence 17508, A
C 18	16.8	70.0	81384	4 US-09-949-016-17422 Sequence 17509, A
C 19	16.6	69.2	601	4 US-09-621-976-171702 Sequence 17510, A
C 20	16.6	69.2	601	4 US-09-949-016-23459 Sequence 17511, A
C 21	16.6	69.2	601	4 US-09-949-016-153865 Sequence 17512, A
C 22	16.6	69.2	601	4 US-09-949-016-15733 Sequence 17513, A
C 23	16.6	69.2	601	4 US-09-949-016-159083 Sequence 17514, A
C 24	16.6	69.2	601	4 US-09-949-016-159084 Sequence 17515, A
C 25	16.6	69.2	1572	4 US-09-107-532A-95 Sequence 17516, A
C 26	16.6	69.2	24847	4 US-09-949-016-16056 Sequence 17517, A
C 27	16.6	69.2	25464	4 US-09-326-480A-4 Sequence 17518, A

RESULT 1
US-08-439-814-4/C
Sequence 4, Application US/08439814
; Patent No. 5968735
; GENERAL INFORMATION:
; APPLICANT: STINN, Ulrike
; APPLICANT: WALTHER, Wolfgang
; TITLE OF INVENTION: VECTOR FOR THE EXPRESSION OF
; TITLE OF INVENTION: THERAPY-RELEVANT GENES
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIVAKDO MARMELSTEIN, MURRAY & ORAM LLP
; STREET: 655 Fifteenth Street, N. W., Suite 330 G
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005-5701
; COMPUTER READABLE FORM:
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/439,814
; FILING DATE: 12-MAY-1995
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: DE P 4238778.7
; FILING DATE: 12-NOV-1992
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: DE PCT/DB93/01086
; FILING DATE: 10-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: KLEENER, Sharon N.
; REGISTRATION NUMBER: 3,6,335
; REFERENCE/DOCKET NUMBER: P1614-5015
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202/638-5000
; TELEFAX: 202/638-4810
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30B (EPO)
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: DE P4238778.7
; FILING DATE: 12-NOV-1992
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/DB93/01086

2183

FILING DATE: 10-NOV-1993
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 508 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

US-08-439-814-4

Query Match 100.0%; Score 24; DB 2; Length 568;
 Best Local Similarity 100.0%; Pred. No. 0.027; Mismatches 0; Indels 0; Gaps 0;
 Matches 24; Conservative 0; MisMatches 0; Indels 0; Gaps 0;

Qy 1 CTTATGAGACGCTTCAAG 24
 Db 203 CTTATGAGACGCTTCAAG 180

RESULT 2

US-08-439-814-3/c

Sequence 3, Application US/08439814
 Patent No. 5968735
 GENERAL INFORMATION:

APPLICANT: STEIN, Ulrike
 APPLICANT: WALTHER, Wolfgang

APPLICANT: VECTOR FOR THE EXPRESSION OF
 TITLE OF INVENTION: THERAPY-RELEVANT GENES

NUMBER OF SEQUENCES: 7
 CORRESPONDENCE ADDRESS:

ADDRESSEE: NIKAIKO, MARMELSTEIN, MURRAY & ORAM LLP
 STREET: 655 Fifteenth Street, N. W., Suite 330 G

CITY: Washington
 STATE: DC
 COUNTRY: USA
 ZIP: 20005-5701

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/439,814
 FILING DATE: 12-MAY-1995
 CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 4238778.7
 FILING DATE: 12-NOV-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE PCT/DE93/01086
 FILING DATE: 10-NOV-1993

ATTORNEY/AGENT INFORMATION:

NAME: KLESNER, Sharon N.
 REGISTRATION NUMBER: 36,335
 REFERENCE/DOCKET NUMBER: P1614-5015

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202/638-5000
 TELEFAX: 202/638-4810

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30B (EPO)
 PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 4238778.7
 FILING DATE: 12-NOV-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: WO PCT/DE93/01086
 FILING DATE: 10-NOV-1993

SEQUENCE CHARACTERISTICS:
 LENGTH: 166 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

US-08-439-814-3

Query Match 100.0%; Score 24; DB 2; Length 1318;
 Best Local Similarity 100.0%; Pred. No. 0.031; Mismatches 0; Indels 0; Gaps 0;
 Matches 24; Conservative 0; MisMatches 0; Indels 0; Gaps 0;

Qy 1 CTTATGAGACGCTTCAAG 24
 Db 953 CTTATGAGACGCTTCAAG 930

RESULT 3

US-08-439-814-2/c

Sequence 2, Application US/08439814
 Patent No. 5968735
 GENERAL INFORMATION:

APPLICANT: STEIN, Ulrike
 APPLICANT: WALTHER, Wolfgang

APPLICANT: VECTOR FOR THE EXPRESSION OF
 TITLE OF INVENTION: THERAPY-RELEVANT GENES

NUMBER OF SEQUENCES: 7
 CORRESPONDENCE ADDRESS:

ADDRESSEE: NIKAIKO, MARMELSTEIN, MURRAY & ORAM LLP
 STREET: 655 Fifteenth Street, N. W., Suite 330 G

CITY: Washington
 STATE: DC
 COUNTRY: USA
 ZIP: 20005-5701

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/439,814
 FILING DATE: 12-MAY-1995
 CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 4238778.7
 FILING DATE: 10-NOV-1993

ATTORNEY/AGENT INFORMATION:

NAME: KLESNER, Sharon N.
 REGISTRATION NUMBER: 36,335
 REFERENCE/DOCKET NUMBER: P1614-5015

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202/638-5000
 TELEFAX: 202/638-4810

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30B (EPO)
 PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 4238778.7
 FILING DATE: 12-NOV-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: WO PCT/DE93/01086
 FILING DATE: 10-NOV-1993

SEQUENCE CHARACTERISTICS:
 LENGTH: 166 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

373

US-08-439-814-2

Query Match 100.0%; Score 24; DB 2; Length 168;
 Best Local Similarity 100.0%; Pred. No. 0.032; 0; Mismatches
 Matches 24; Conservative 0; Indels 0; Gaps 0;

Qy 1 CTTATGAGACAGCTTCAAG 24

Db 1323 CTTATGAGACAGCTTCAAG 1300

RESULT 4

US-08-439-814-1/C

Sequence 1, Application US/08439814
 Patent No. 5568735

GENERAL INFORMATION:

APPLICANT: STEIN, Ulrike

TITLE OF INVENTION: VECTOR FOR THE EXPRESSION OF

TITLE OF INVENTION: THERAPY-RELEVANT GENES

NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESS:

ADDRESSEE: NIKAIKO, MARMELSTEIN, MURRAY & ORAM LLP

STREET: 655 Fifteenth Street, N. W., Suite 330 G

CITY: Washington

STATE: DC

COUNTRY: USA

ZIP: 20005-5011

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, version #1.3.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/439,814

FILING DATE: 12-MAY-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 4238778.7

FILING DATE: 12-NOV-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE PCT/DE93/01086

FILING DATE: 10-NOV-1993

ATTORNEY/AGENT INFORMATION:

NAME: KLESNER, Sharon N.

REGISTRATION NUMBER: 36,135

REFERENCE/DOCKET NUMBER: P1614-5015

TELECOMMUNICATION INFORMATION:

TELEPHONE: 202/638-5000

TELEFAX: 202/638-4910

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, version #1.3.0B (EPO)

PRIOR APPLICATION DATA:

APPLICATION NUMBER: DE P 4238778.7

FILING DATE: 12-NOV-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: WO PCT/DE93/01086

FILING DATE: 10-NOV-1993

INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 2090 base pairs
 TYPE: nucleic acid
 STRANDBEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

US-08-439-814-1

Query Match 100.0%; Score 24; DB 2; Length 2090;
 Best Local Similarity 100.0%; Pred. No. 0.033;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTTATGAGACAGCTTCAAG 24

Db 1725 CTTATGAGACAGCTTCAAG 1702

RESULT 5

US-09-949-016-70889/C

Sequence 70889, Application US/09949016
 Patent No. 6812339

GENERAL INFORMATION:

APPLICANT: VENTER, J. Craig et al.

TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED

WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF

FILE REFERENCE: CL001307

CURRENT APPLICATION NUMBER: US/09/949,016

CURRENT FILING DATE: 2000-10-03

PRIOR APPLICATION NUMBER: 60/231,498

PRIOR FILING DATE: 2000-10-03

PRIOR APPLICATION NUMBER: 60/241,755

PRIOR FILING DATE: 2000-10-20

PRIOR APPLICATION NUMBER: 60/237,768

PRIOR FILING DATE: 2000-10-03

PRIOR APPLICATION NUMBER: 60/231,498

PRIOR FILING DATE: 2000-09-08

NUMBER OF SEQ ID NOS: 20712

SOFTWARE: FastSEQ for Windows Version 4.0

SEQ ID NO: 70890

LENGTH: 601

TYPE: DNA

ORGANISM: Human

US-09-949-016-70889

Query Match 71.7%; Score 17.2; DB 4; Length 601;

Best Local Similarity 86.4%; Pred. No. 51; 0; Mismatches

Matches 19; Conservative 0; Indels 3; Gaps 0;

Qy 2 TTATGAGACAGCTTCAAG 23

Db 95 TTATGAGACAGCTTCAAG 74